• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

ECTRIMS 2018 DAILY REPORT – WEDNESDAY EDITION

October 10, 2018  

ECTRIMS Poster Picks – Wednesday, October 10

October 10, 2018  

Laquinimod program cancelled in MS

September 6, 2018  

Heart disease associated with atrophy in MS

August 15, 2018  

Predictors of switching therapies in MS – real-world results

August 1, 2018  

Exploring therapeutic inertia in multiple sclerosis

July 11, 2018  

Update on oral cladribine – Effect on lymphocytes and safety data

May 9, 2018  

MS therapeutics: 1 withdrawal, 1 setback

March 5, 2018  

DMF: the Canadian MS patient experience

February 28, 2018  

ECTRIMS/EAN publish new MS treatment guidelines

January 30, 2018  
Previous
24
25
26
27
28
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Management of refractory epilepsy: highlights from ILAE 2025 posted on October 29, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions